(Q34211486)

31 July 2017

title

I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors (English)

1 reference

31 July 2017

Maria L Carlsson

1

1 reference

31 July 2017

Ethan S Burstein

2

1 reference

31 July 2017

Angélica Kloberg

3

1 reference

31 July 2017

Sarah Hansson

4

1 reference

31 July 2017

Arja Schedwin

5

1 reference

31 July 2017

Marie Nilsson

6

1 reference

31 July 2017

Johan P Rung

7

1 reference

31 July 2017

Arvid Carlsson

8

1 reference

31 July 2017

publication date

28 August 2011

1 reference

Journal of Neural Transmission

31 July 2017

published in

1 reference

31 July 2017

volume

118

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1511-1522

1 reference

Schizophrenia: from dopamine to glutamate and back

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0704-8

Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21874578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21874578

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00702-011-0704-8

1 reference

31 July 2017

1 reference